Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT04550260Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 16
01
Overview
A Phase 3 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AstraZeneca. Started Oct 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04550260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550260.